Online Enquiry
Subscribe
Log in / New User
Retrieve Password
此页面上的内容需要较新版本的 Adobe Flash Player。
切换导航
Home
Pharma China Web Edition
Pharma China Archives
Online Databases
Subscription/Download
Event Calendar
China Pharma Providers
About Us
Location:
Home
> Pharma China Web Edition
News
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
Feature articles
Editorials
Focus Articles
Expert Opinions
Interviews
Case Studies
Company Profiles
News in Focus
Editor's Picks
Full Text
Title
Subscribe to Pharma China
Online Enquiry
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
Editorials
Focus Articles
Expert Opinions
Interviews
Case Studies
Company Profiles
News in Focus
Editor's Picks
ONLINE ENQUIRY
WiCON International Group
Bellevue, WA 98007, USA
info@pharmachinaonline.com
WiCON International Co. Ltd.
Osaka, Japan
info@pharmachinaonline.com
News
7/3/2025
Vaccine Sales Collapse in China as MNCs Struggle with Local Competitio...
7/3/2025
AbbVie's Venclexta Approved in China for Second-Line Treatment of del1...
7/3/2025
Eli Lilly's Tirzepatide Approved in China for Treatment of Obstructive...
7/3/2025
Hengrui Medicine Gains NMPA Approval for Novel Dry Eye Treatment SHR80...
7/3/2025
CTTQ's Homegrown rFVIIa Wins NMPA Approval for Bleeding Disorders
7/3/2025
Belief BioMed Unveils 4-Year Follow-Up Data for Hemophilia B Gene Ther...
7/3/2025
Cloudbreak Pharma Debuts on HKEX, Raising HK$612 Million in IPO
7/3/2025
Akeso Launches Clinical Trials for First Bispecific ADC
7/3/2025
Dizal's Lung Cancer Pill Gains FDA Nod, Challenging Rivals in EGFR Exo...
7/3/2025
CStone Expands Pipeline with Novel BsAb Targeting Autoimmune and Infla...
7/2/2025
API China 2025 Ends with High Attendance and Global Industry Participa...
7/2/2025
China to Eliminate CD Submission Requirement for Clinical Trial Databa...
7/2/2025
China Issues Technical Guidance for Clinical Resistance Studies of Ant...
7/2/2025
HanchorBio and Henlius Ink Major Licensing Deal for I/O Candidate HCB1...
7/2/2025
InventisBio Launches First Phase III Trial of TYK2 Inhibitor D‑2570 i...
7/2/2025
Betta's Tibremciclib Approved in China for Advanced HR+/HER2– Breast ...
7/2/2025
NMPA Grants Marketing Approval to GeneScience's Firsekibart for Acute ...
7/2/2025
China Grants Conditional Approval to Bebetter Medicine's Ifupinostat f...
7/2/2025
Simcere's Suvemcitug Approved in China for Platinum-Resistant Ovarian ...
7/2/2025
Biokin's Iza-bren Achieves Primary Endpoint in Phase III Trial for Nas...
7/1/2025
Record China Pharma Monopoly Fine Sends Strong Deterrent Signal, Exper...
7/1/2025
Jinhua Conba and EVA Forge Strategic Partnership to Strengthen China-M...
7/1/2025
China's STAR Market Approves Heyuan Biotech's IPO
7/1/2025
China Launches New Tax Incentives to Boost Foreign Companies' Reinvest...
7/1/2025
Zai Lab-Backed FORTITUDE-101 Trial Hits Key Milestone in...
7/1/2025
Revolution Medicines and Summit Therapeutics Launch RAS-Targeting Comb...
7/1/2025
Hengrui's Ivarmacitinib Approved in China for Severe Alopecia Areata
7/1/2025
Adagene Secures Up to $25 Million from Sanofi to Advance SAFEbody Pipe...
7/1/2025
Healthgen Biotech IPO Approved, First STAR Market Biopharma Case Since...
7/1/2025
NHSA Seeks Public Input on 2025 Drug Reimbursement and Innovation List...
Page:
1
/
53
Total number of articles:
1570
:
[First]
[<<]
[1]
[2]
[3]
[4]
[5]
[>>]
[End]
News
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
FEATURE ARTICLES
Editorials
Focus Articles
Expert Opinions
Interviews
Case Studies
Company Profiles
News in Focus
Editor's Picks
GENERAL INFORMATION
TERMS & CONDITIONS OF USE
Download Info
Contact Us
Site map
|
Contact Us
|
Links
© Wicon International Group
×
Join the mailing list
We will e-mail you the most critical news and developments about China's healthcare sector, in real time and absolutely free.
name:
e-mail:
company:
submit